484
Views
0
CrossRef citations to date
0
Altmetric
Letter to the editor

Letter to the editor

, &
Pages 1051-1053 | Published online: 24 May 2012
 

Online summary

Re: Cost-effectiveness analysis of disease modifying drugs (β-interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. JME 2012;15(3):424–33.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.